We use cookies for a better user experience. Read our Privacy Policy

I Agree

Alpha 1 Antitrypsin Deficiency Treatment Market

Alpha 1 Antitrypsin Deficiency Treatment Market (Treatment Type - Augmentation Therapy, Bronchodilators, Corticosteroids, and Oxygen Therapy; End-user - Hospitals, Specialty Clinics, and Pharmacies; Route of Administration - Parenteral, Inhalation, and Oral) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

Alpha 1 Antitrypsin Deficiency Treatment Market: Overview

As per the latest professional survey report on the global alpha 1 antitrypsin deficiency treatment market by the Transparency Market Research, the industry is anticipated to rise at a significant growth rate of 10.1 % over the forecast period, i.e. 2019 to 2027. Furthermore, the research report also states that the global alpha 1 antitrypsin deficiency treatment market was evaluated at US$ 1.4 billion in the year 2018. Some of the major driving factors that are supplementing the demand in the global alpha 1 antitrypsin deficiency treatment market are increasing prevalence as well as high incidence of various respiratory diseases and increasing awareness amongst public about AAT deficiency and its treatment options.

As per the study by the World Health Organization, approximately 65 million people around the world suffer from chronic obstructive pulmonary disease or COPD. The study also states that around 3 million people die owing to the same disorder all over the world. Along with this, rising government initiatives for developing and expanding the plasma and blood products is also fueling the demand within the global alpha 1 antitrypsin deficiency treatment market in coming years. Moreover, the increase in the prescription for combination therapies is also expected to fuel the growth within the global alpha 1 antitrypsin deficiency treatment market in near future.

On the other hand, the severe side effects associated with the treatment solutions within the global alpha 1 antitrypsin deficiency treatment market, such as chest pain, sinusitis, back pain, and rhinorrhea can restrict the growth within the industry in coming years. Furthermore, high cost associated with therapy as well as the low diagnostic rate for the disease may also negatively impact the growth within the global alpha 1 antitrypsin deficiency treatment market over the forecast period.

The segments within the global alpha 1 antitrypsin deficiency treatment market based on the type of treatment include bronchodilator, oxygen therapy, corticosteroids, and augmentation therapy, including prolastin, glassia, aralast, zemaira or respreeza, among others. The segments in the global alpha 1 antitrypsin deficiency treatment market classified by the route of administration are inhalations, parenteral, and oral. Major end users for the products and solutions offered by the players functional within the global alpha 1 antitrypsin deficiency treatment market include hospitals, specialty clinics, and pharmacies.

new fa global alpha 1 antitrypsin deficiency treatment market

To know the scope of our report Get a Sample on Alpha 1 Antitrypsin Deficiency Treatment Market

North America Leads the Alpha 1 Antitrypsin Deficiency Treatment Market

Leading nations as well as key regions within the global alpha 1 antitrypsin deficiency treatment market include North America (including Canada and the United States), Europe (including the United Kingdom, Italy, Germany, France, Spain, and rest of the Europe), Asia Pacific (including Japan, Australia and New Zealand, China, India, and rest of the Asia Pacific), Latin America (including Mexico, Brazil, and rest of the Latin America), and Middle East and Africa (including South Africa, Gulf Cooperation Council countries, and rest of the Middle East and Africa). Regionally, the North America region leads the global alpha 1 antitrypsin deficiency treatment market in terms of industry share.

Key drivers influencing the growth within the global alpha 1 antitrypsin deficiency treatment market in North America include rising investments by the major players in the region aimed at furthering the research and development activities, enhanced rate of diagnostics for AAT deficiency, and increasing prevalence of respiratory disorders in the region. On the other hand, Europe is anticipated to emerge as the most promising regional market within the global alpha 1 antitrypsin deficiency treatment market over the forecast period. Some of the major factors positively influencing the demand dynamics within the global alpha 1 antitrypsin deficiency treatment market in Europe are increasing research and development initiatives aimed at better treatment of various respiratory disorders, rising demand owing to increased awareness amongst the consumers about AAT deficiency and treatment therapeutics, and increase in the elderly or geriatric population that is more prone to various kinds of respiratory diseases.

Get a glimpse of the in-depth analysis through our Report Brochure

Players in Alpha 1 Antitrypsin Deficiency Treatment Market Focused on Gaining Regulatory Approvals

The competitive landscape of the global alpha 1 antitrypsin deficiency treatment market is considered to be highly fragmented, with a number of international players holding a major industry share. Few of the major incumbent players and vendors functional within the global alpha 1 antitrypsin deficiency treatment market include Takeda Pharmaceutical Company Limited, Kamada Pharmaceuticals, AstraZeneca, Pfizer, Inc., LFB Biomedicaments S. A., Grifols, S. A., CSL Behring, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, and Teva Pharmaceutical Industries Ltd., among others. Several prominent players and manufacturers within the global alpha 1 antitrypsin deficiency treatment market are focused on gaining regulatory approvals for their new products as well as on developing new and innovative products.

Furthermore, some of the key corporate development strategies adopted by the players functional within the global alpha 1 antitrypsin deficiency treatment market include collaborative agreements as well as mergers and acquisitions. For example, Kamada Ltd., extended their strategic supply agreement with the Takeda Pharmaceutical Company Limited in September of 2019. This move will help Kamada to produce Alpha 1 Proteinase Inhibitor for humans called ‘Glassia’ through 2021. Furthermore, Alpha 1 proteinase inhibitor for humans by the CSL Behring called ‘Zemaira’ was approved by the United States Food and Drug Association in April of 2019. This move will allow the company to develop and offer these inhibitors in 4 as well as 5 gram vials in the United States, aimed at the treatment of alpha 1 antitrypsin deficiency.

Expanding operations in future? To get the perfect launch ask for a custom report

The Global Alpha-1 Antitrypsin Deficiency Treatment Market has been segmented as follows:

by Treatment Type

  • Augmentation Therapy
    • Aralast
    • Prolastin
    • Zemaira/Respreeza
    • Glassia
  • Bronchodilator
  • Corticosteroids
  • Oxygen Therapy
  • Others

by Route of Administration

  • Parenteral
  • Inhalations
  • Oral

by End-User

  • Specialty Clinics
  • Hospitals
  • Pharmacies

by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Alpha 1 Antitrypsin Deficiency Treatment Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the anticipated CAGR of the alpha 1 antitrypsin deficiency treatment market in the forecast period?

Alpha 1 antitrypsin deficiency treatment market will expand at a healthy CAGR of 10.1% over the forecast period of 2019 to 2027

What are the key driving factors for the growth of the alpha 1 antitrypsin deficiency treatment market?

Alpha 1 antitrypsin deficiency treatment market is driven by high incidence rate and rising prevalence of various respiratory diseases

Which region is expected to project the highest market share in the global alpha 1 antitrypsin deficiency treatment market?

North America accounted for a major share of the global alpha 1 antitrypsin deficiency treatment market

What are the end-use segments in the alpha 1 antitrypsin deficiency treatment market?

The end-use segments in alpha 1 antitrypsin deficiency treatment market are hospitals, specialty clinics, and pharmacies

Who are the key players in the global alpha 1 antitrypsin deficiency treatment market?

Key players in the global alpha 1 antitrypsin deficiency treatment market include Takeda Pharmaceutical Company Limited, Kamada Pharmaceuticals, AstraZeneca, Pfizer, Inc., LFB Biomedicaments S.A.

1. Preface

    1.1. Report Scope and Market Segmentation

    1.2. Research Highlights

2. Assumptions and Research Methodology

    2.1. Assumptions

    2.2. Research Methodology

3. Executive Summary: 

    3.1. Global Alpha-1 Antitrypsin Deficiency Treatment: Market Snapshot         

    3.2. Market Share Analysis by Region, 2018

4. Market Overview

    4.1. Introduction

        4.1.1. Treatment Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Alpha 1 Antitrypsin Deficiency Treatment Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

    4.5. Porter’s Five Force Analysis

5. Key Insights

    5.1. Alpha-1 Antitrypsin Deficiency Treatment Market: Value Chain Analysis

    5.2. Comparative Brand Analysis

    5.3. Porter’s Five Forces Analysis 

    5.4. Epidemiology: Alpha-1 Antitrypsin Deficiency

    5.5. Pipeline Analysis: Alpha-1 Antitrypsin Deficiency Treatment Market

    5.6. Clinical Trials: Alpha-1 Antitrypsin Deficiency Treatment Market

6. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by Treatment

    6.1. Introduction 

    6.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment

    6.3. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by Treatment, 2017-2027

        6.3.1. Augmentation Therapy

            6.3.1.1. Aralast

            6.3.1.2. Prolastin

            6.3.1.3. Zemaira/Respreeza

            6.3.1.4. Glassia

        6.3.2. Bronchodilator

        6.3.3. Corticosteroids

        6.3.4. Oxygen Therapy

        6.3.5. Others

    6.4. Market Attractiveness Analysis, by Treatment, 2019-2027

7. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by End-user, 2017-2027

    7.1. Introduction 

    7.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-User

    7.3. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by End-user, 2017-2027

        7.3.1. Specialty Clinics

        7.3.2. Hospitals

        7.3.3. Pharmacies 

    7.4. Market Attractiveness, by End-User, 2019-2027

8. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by Route of Administration, 2017-2027

    8.1. Introduction 

    8.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration

        8.2.1. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by Route of Administration , 2017-2027

        8.2.2. Parenteral

        8.2.3. Inhalation

        8.2.4. Oral

    8.3. Market Attractiveness by Route of Administration, 2019-2027

9. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by Region, 2017-2027

    9.1. Global Alpha-1 Antitrypsin Deficiency Treatment Market, Regional Outlook

    9.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Region

    9.3. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by Region, 2017-2027

    9.4. Market Attractiveness Analysis, by Region, 2019-2027

10. North America Alpha-1 Antitrypsin Deficiency Treatment Market Analysis

    10.1. Market Overview

    10.2. Market Analysis, by Treatment

        10.2.1. Market Value Share Analysis, by Treatment

        10.2.2. Market Value Forecast Forecast, by Treatment, 2017-2027

            10.2.2.1. Augmentation Therapy

                10.2.2.1.1. Aralast

                10.2.2.1.2. Prolastin

                10.2.2.1.3. Zemaira/Respreeza

                10.2.2.1.4. Glassia

            10.2.2.2. Bronchodilator

            10.2.2.3. Corticosteroids

            10.2.2.4. Oxygen Therapy

            10.2.2.5. Others

    10.3. Market Value Forecast, by End-user, 2017-2027

        10.3.1. Market Value Share Analysis, by End-user

        10.3.2. Market Value Forecast Forecast, by End-user

            10.3.2.1. Specialty Clinics

            10.3.2.2. Hospitals

            10.3.2.3. Pharmacies

    10.4. Market Value Forecast, by Route of Administration, 2017-2027

        10.4.1. Market Value Share Analysis, by Route of Administration

        10.4.2. Market Value Forecast Forecast, by Route of Administration

            10.4.2.1. Parenteral

            10.4.2.2. Inhalation

            10.4.2.3. Oral

    10.5. Market Value Forecast Forecast, by Country, 2017-2027

        10.5.1. Market Value Share Analysis, by Country

        10.5.2. Market Value Forecast, by Country, 2017–2027

            10.5.2.1. U.S.

            10.5.2.2. Canada

    10.6. Market Attractiveness Analysis, 2019-2027

        10.6.1. By Treatment

        10.6.2. By End-user

        10.6.3. By Route of Administration

        10.6.4. By Country 

11. Europe Alpha-1 Antitrypsin Deficiency Treatment Market Analysis

    11.1. Market Overview

    11.2. Market Analysis, by Treatment

        11.2.1. Market Value Share Analysis, by Treatment

        11.2.2. Market Value Forecast, by Treatment, 2017-2027

            11.2.2.1. Augmentation Therapy

                11.2.2.1.1. Aralast

                11.2.2.1.2. Prolastin

                11.2.2.1.3. Zemaira/Respreeza

                11.2.2.1.4. Glassia

            11.2.2.2. Bronchodilator

            11.2.2.3. Corticosteroids

            11.2.2.4. Oxygen Therapy

            11.2.2.5. Others

    11.3. Market Value Forecast, by End-user

        11.3.1. Market Value Share Analysis, by End-user

        11.3.2. Market Value Forecast, by End-user, 2017-2027

            11.3.2.1. Specialty Clinics

            11.3.2.2. Hospitals

            11.3.2.3. Pharmacies

    11.4. Market Value Forecast, by Route of Administration, 2017-2027

        11.4.1. Market Value Share Analysis, by Route of Administration

        11.4.2. Market Value Forecast, by Route of Administration

            11.4.2.1. Parenteral

            11.4.2.2. Inhalation

            11.4.2.3. Oral

    11.5. Market Value Forecast, by Country

        11.5.1. Market Value Share Analysis, by Country

        11.5.2. Market Value Forecast, by Country, 2017-2027

            11.5.2.1. U.K.

            11.5.2.2. Germany

            11.5.2.3. France 

            11.5.2.4. Italy

            11.5.2.5. Spain

            11.5.2.6. Rest of Europe

    11.6. Market Attractiveness Analysis, 2019-2027

        11.6.1. By Treatment

        11.6.2. By End-user

        11.6.3. By Route of Administration

        11.6.4. By Country

12. Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Analysis

    12.1. Market Overview

    12.2. Market Analysis, by Treatment

        12.2.1. Market Value Share Analysis, by Treatment

        12.2.2. Market Value Forecast, by Treatment, 2017-2027

            12.2.2.1. Augmentation Therapy

                12.2.2.1.1. Aralast

                12.2.2.1.2. Prolastin

                12.2.2.1.3. Zemaira/Respreeza

                12.2.2.1.4. Glassia

            12.2.2.2. Bronchodilator

            12.2.2.3. Corticosteroids

            12.2.2.4. Oxygen Therapy

            12.2.2.5. Others

    12.3. Market Value Forecast, by End-user

        12.3.1. Market Value Share Analysis, by End-user

        12.3.2. Market Value Forecast, by End-user, 2017-2027

            12.3.2.1. Specialty Clinics

            12.3.2.2. Hospitals

            12.3.2.3. Pharmacies

    12.4. Market Value Forecast, by Route of Administration

        12.4.1. Market Value Share Analysis, by Route of Administration

        12.4.2. Market Value Forecast, by Route of Administration, 2017-2027

            12.4.2.1. Parenteral

            12.4.2.2. Inhalation

            12.4.2.3. Oral

    12.5. Market Value Forecast, by Country, 2017-2027

        12.5.1. Market Value Share Analysis, by Country

        12.5.2. Market Value Forecast, by Country, 2017-2027

            12.5.2.1. China

            12.5.2.2. Japan

            12.5.2.3. India

            12.5.2.4. Australia & New Zealand

            12.5.2.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis, 2019-2027

        12.6.1. By Treatment

        12.6.2. By End-user

        12.6.3. By Route of Administration

        12.6.4. By Country

13. Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Analysis

    13.1. Market Overview

    13.2. Market Analysis, by Treatment

        13.2.1. Market Value Share Analysis, by Treatment

        13.2.2. Market Value Forecast, by Treatment, 2017-2027

            13.2.2.1. Augmentation Therapy

                13.2.2.1.1. Aralast

                13.2.2.1.2. Prolastin

                13.2.2.1.3. Zemaira/Respreeza

                13.2.2.1.4. Glassia

            13.2.2.2. Bronchodilator

            13.2.2.3. Corticosteroids

            13.2.2.4. Oxygen Therapy

            13.2.2.5. Others

    13.3. Market Value Forecast, by End-user, 2017-2027

        13.3.1. Market Value Share Analysis, by End-user

        13.3.2. Market Value Forecast, by End-user, 2017-2027

            13.3.2.1. Specialty Clinics

            13.3.2.2. Hospitals

            13.3.2.3. Pharmacies

    13.4. Market Value Forecast, by Route of Administration

        13.4.1. Market Value Share Analysis, by Route of Administration

        13.4.2. Market Value Forecast, by Route of Administration, 2017-2027

            13.4.2.1. Parenteral

            13.4.2.2. Inhalation

            13.4.2.3. Oral

    13.5. Market Value Forecast, by Country

        13.5.1. Market Value Share Analysis, by Country

        13.5.2. Market Value Forecast, by Country, 2017-2027

            13.5.2.1. Brazil

            13.5.2.2. Mexico

            13.5.2.3. Rest of LATAM

    13.6. Market Attractiveness Analysis, 2019-2027

        13.6.1. By Treatment

        13.6.2. By End-user

        13.6.3. By Route of Administration

        13.6.4. By Country

14. Middle East and Africa Alpha-1 Antitrypsin Deficiency Treatment Market Analysis

    14.1. Market Overview

    14.2. Market Analysis, by Treatment

        14.2.1. Market Value Share Analysis, by Treatment

        14.2.2. Market Value Forecast, by Treatment, 2017-2027

            14.2.2.1. Augmentation Therapy

                14.2.2.1.1. Aralast

                14.2.2.1.2. Prolastin

                14.2.2.1.3. Zemaira/Respreeza

                14.2.2.1.4. Glassia

            14.2.2.2. Bronchodilator

            14.2.2.3. Corticosteroids

            14.2.2.4. Oxygen Therapy

            14.2.2.5. Others

    14.3. Market Value Forecast, by End-user

        14.3.1. Market Value Share Analysis, by End-user

        14.3.2. Market Value Forecast, by End-user, 2017-2027

            14.3.2.1. Specialty Clinics

            14.3.2.2. Hospitals

            14.3.2.3. Pharmacies

    14.4. Market Value Forecast, by Route of Administration

        14.4.1. Market Value Share Analysis, by Route of Administration

        14.4.2. Market Value Forecast, by Route of Administration, 2017-2027

            14.4.2.1. Parenteral

            14.4.2.2. Inhalation

            14.4.2.3. Oral

    14.5. Market Value Forecast, by Country

        14.5.1. Market Value Share Analysis, by Country

        14.5.2. Market Value Forecast, by Country, 2017-2027

            14.5.2.1. GCC Countries

            14.5.2.2. South Africa

            14.5.2.3. Rest of MEA

    14.6. Market Attractiveness Analysis, 2019-2027

        14.6.1. By Treatment

        14.6.2. By End-user

        14.6.3. By Route of Administration

        14.6.4. By Country

15. Competition Landscape

    15.1. Alpha-1 Antitrypsin Deficiency Treatment Market Share Analysis, by Company (2016)

    15.2. Company Profiles

        15.2.1. Grifols, S.A.

            15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.1.2. Product Portfolio

            15.2.1.3. SWOT Analysis

            15.2.1.4. Strategic Overview

        15.2.2. AstraZeneca

            15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.2.2. Product Portfolio

            15.2.2.3. SWOT Analysis

            15.2.2.4. Strategic Overview

        15.2.3. Teva Pharmaceutical Industries Ltd.

            15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.3.2. Product Portfolio

            15.2.3.3. SWOT Analysis

            15.2.3.4. Strategic Overview

        15.2.4. Boehringer Ingelheim GmbH

            15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.4.2. Product Portfolio

            15.2.4.3. SWOT Analysis

            15.2.4.4. Strategic Overview

        15.2.5. GlaxoSmithKline Plc.

            15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.5.2. Product Portfolio

            15.2.5.3. SWOT Analysis

            15.2.5.4. Strategic Overview

        15.2.6. CSL Behring LLC

            15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.6.2. Product Portfolio

            15.2.6.3. SWOT Analysis

            15.2.6.4. Strategic Overview

        15.2.7. Takeda Pharmaceutical Company Limited

            15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.7.2. Product Portfolio

            15.2.7.3. SWOT Analysis

            15.2.7.4. Strategic Overview

        15.2.8. Pfizer Inc.

            15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.8.2. Product Portfolio

            15.2.8.3. SWOT Analysis

            15.2.8.4. Strategic Overview

        15.2.9. LFB Biomedicaments S.A.

            15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.9.2. Product Portfolio

            15.2.9.3. SWOT Analysis

            15.2.9.4. Strategic Overview

        15.2.10. Kamada Ltd

            15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.10.2. Product Portfolio

            15.2.10.3. SWOT Analysis

            15.2.10.4. Strategic Overview

List of Tables

Table 01: Comparative Analysis of Approved Alpha-1 Antitrypsin Replacement Therapy Brands

Table 02: Pipeline Analysis: Alpha-1 Antitrypsin Deficiency Treatment Market

Table 03: Clinical Trials: Alpha-1 Antitrypsin Deficiency Treatment Market

Table 04: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Treatment, 2017–2027

Table 05: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by End-user, 2017–2027

Table 06: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Route of Administration, 2017–2027

Table 07: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Region, 2017–2027

Table 08: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Treatment, 2017–2027

Table 09: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by End-user, 2017–2027

Table 10: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Route of Administration, 2017–2027

Table 11: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Country, 2017–2027

Table 12: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Treatment, 2017–2027

Table 13: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by End-user, 2017–2027

Table 14: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Route of Administration, 2017–2027

Table 15: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Country, 2017–2027

Table 16: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Treatment, 2017–2027

Table 17: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by End-user, 2017–2027

Table 18: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Route of Administration, 2017–2027

Table 19: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Country, 2017–2027 

Table 20: Table 17: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Treatment, 2017–2027

Table 21: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by End-user, 2017–2027

Table 22: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Route of Administration, 2017–2027

Table 23: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Country, 2017–2027

Table 24: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Treatment Type, 2017–2027

Table 25: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by End-user, 2017–2027

Table 26: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Route of Administration, 2017–2027

Table 27: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Country, 2017–2027

List of Figures

Figure 01: Alpha-1 Antitrypsin Deficiency Treatment Market Snapshot

Figure 02: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast Forecast and Y-o-Y Growth (%), 2017–2027

Figure 03: Market Value Share By Treatment Type (2018)

Figure 04: Market Value Share By End-user (2018)

Figure 05: Market Value Share By Route of Administration (2018)

Figure 06: Market Value Share By Region(2018)

Figure 07: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 08: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Augmentation Therapy, 2017–2027

Figure 09: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Bronchodilators, 2017–2027

Figure 10: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Corticosteroids, 2017–2027

Figure 11: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oxygen Therapy, 2017–2027

Figure 12: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

Figure 13: Global Aralast Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

Figure 14: Global Prolastin Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

Figure 15: Global Zemaira/Respreeza Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

Figure 16: Global Glassia Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

Figure 17: Global Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment, 2019-2027

Figure 18: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2018 and 2027

Figure 19: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Specialty Clinics, 2017–2027

Figure 20: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2017–2027

Figure 21: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pharmacies, 2017–2027

Figure 22: Global Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user, 2019-2027

Figure 23: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 24: Global Parenteral Market Revenue, US$ Mn,2017-2027

Figure 25: Global Inhalation Market Revenue, US$ Mn, 2017-2027

Figure 26: Global Oral Market Revenue, US$ Mn, 2017–2027

Figure 27: Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Route of Administration, 2019-2027

Figure 28: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Region, 2018 and 2027

Figure 29: Global Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Region, 2019-2027

Figure 30: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, 2017–2027

Figure 31: North America Market Attractiveness Analysis, by Country, 2019-2027

Figure 32: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 33: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2018 and 2027

Figure 34: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 35: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2018 and 2027

Figure 36: North America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment, 2019-2027

Figure 37: North America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user, 2019-2027

Figure 38: North America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Route of Administration, 2019-2027

Figure 39: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, 2017–2027

Figure 40: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Country, 2019-2027

Figure 41: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 42: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2018 and 2027

Figure 43: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 44: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2018 and 2027

Figure 45: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment, 2019-2027

Figure 46: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user, 2019-2027

Figure 47: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Route of Administration, 2019-2027

Figure 48: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, 2017–2027

Figure 49: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Country, 2019-2027

Figure 50: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 51: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2018 and 2027

Figure 52: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 53: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2018 and 2027

Figure 54: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment, 2019-2027

Figure 55: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user, 2019-2027

Figure 56: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Route of Administration, 2019-2027

Figure 57: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, 2017–2027

Figure 58: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Country, 2019-2027

Figure 59: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 60: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2018 and 2027

Figure 61: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 62: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2018 and 2027

Figure 63: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment, 2019-2027

Figure 64: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user, 2019-2027

Figure 65: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Route of Administration, 2019-2027

Figure 66: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, 2017–2027

Figure 67: Middle East & Africa Market Attractiveness Analysis, by Country, 2019-2027

Figure 68: Middle East & Africa Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 69: Middle East & Africa Market Value Share Analysis, by End-user, 2018 and 2027

Figure 70: Middle East & Africa Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 71: Middle East & Africa Market Value Share Analysis, by Country, 2018 and 2027

Figure 72: Middle East & Africa Market Attractiveness Analysis, by Treatment, 2019-2027

Figure 73: Middle East & Africa Market Attractiveness Analysis, by End-user, 2019-2027

Figure 73: Middle East & Africa Market Attractiveness Analysis, by Route of Administration, 2019-2027

Figure 75: Global Alpha-1 Antitrypsin Deficiency Treatment Market Share Analysis, by Company (2018)

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

186

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved